CN113939309A - 使用sEphB4-HSA融合蛋白治疗癌症 - Google Patents

使用sEphB4-HSA融合蛋白治疗癌症 Download PDF

Info

Publication number
CN113939309A
CN113939309A CN202080036834.1A CN202080036834A CN113939309A CN 113939309 A CN113939309 A CN 113939309A CN 202080036834 A CN202080036834 A CN 202080036834A CN 113939309 A CN113939309 A CN 113939309A
Authority
CN
China
Prior art keywords
cancer
treatment
sephb4
various embodiments
ephrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080036834.1A
Other languages
English (en)
Chinese (zh)
Inventor
V·卡拉斯诺佩洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vascular Gene Therapy Co
Original Assignee
Vascular Gene Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Gene Therapy Co filed Critical Vascular Gene Therapy Co
Publication of CN113939309A publication Critical patent/CN113939309A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080036834.1A 2019-03-17 2020-03-17 使用sEphB4-HSA融合蛋白治疗癌症 Pending CN113939309A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962819642P 2019-03-17 2019-03-17
US62/819,642 2019-03-17
US201962819725P 2019-03-18 2019-03-18
US62/819,725 2019-03-18
PCT/US2020/023215 WO2020190977A1 (en) 2019-03-17 2020-03-17 Treatment of cancers using sephb4-hsa fusion proteins

Publications (1)

Publication Number Publication Date
CN113939309A true CN113939309A (zh) 2022-01-14

Family

ID=72520496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080036834.1A Pending CN113939309A (zh) 2019-03-17 2020-03-17 使用sEphB4-HSA融合蛋白治疗癌症

Country Status (8)

Country Link
US (1) US20220249621A1 (https=)
EP (1) EP3941512A4 (https=)
JP (1) JP7809324B2 (https=)
KR (1) KR20220015375A (https=)
CN (1) CN113939309A (https=)
AU (1) AU2020241963A1 (https=)
CA (1) CA3133437A1 (https=)
WO (1) WO2020190977A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007633A (zh) * 2019-02-13 2022-02-01 血管基因治疗公司 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4168019A4 (en) * 2020-06-17 2024-07-31 4C Biomed Services Ltd. ANTIBODIES AGAINST EPHB2 AND ITS USE IN COMBINATION THERAPY
KR20230106607A (ko) * 2020-10-11 2023-07-13 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법
CA3211742A1 (en) * 2021-03-18 2022-09-22 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
US20250123284A1 (en) * 2021-09-07 2025-04-17 Vasgene Therapeutics Inc Diagnostic methods for cancer using ephrinb2 expression
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932604A (zh) * 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
CN114007633A (zh) * 2019-02-13 2022-02-01 血管基因治疗公司 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932604A (zh) * 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
CN114007633A (zh) * 2019-02-13 2022-02-01 血管基因治疗公司 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT02717156 (clinicaltrials.gov)", HTTPS://CLASSIC.CLINICALTRIALS.GOV/CT2/HISTORY/NCT02717156?V_6=VIEW#STUDYPAGETOP, 17 May 2018 (2018-05-17), pages 2 - 4 *
"History of Changes for Study: NCT03049618 (clinicaltrials.gov)", HTTPS://CLASSIC.CLINICALTRIALS.GOV/CT2/HISTORY/NCT03049618?V_3=VIEW#STUDYPAGETOP, 30 March 2018 (2018-03-30), pages 2 - 3 *
ALESSIO LODOLA等: "Targeting Eph/ephrin system in cancer therapy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 142, 18 July 2017 (2017-07-18), pages 3 - 5 *
REN LIU等: "EphB4 as a therapeutic target in mesothelioma", BMC CANCER, vol. 13, 30 May 2013 (2013-05-30), pages 1 - 7 *
SHILPA BHATIA等: "Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers", CANCER RES, vol. 79, no. 10, 20 March 2019 (2019-03-20), pages 2722 - 2735, XP055979528, DOI: 10.1158/0008-5472.CAN-18-3257 *
SUSHIL KUMAR等: "Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer", ONCOIMMUNOLOGY, vol. 7, no. 1, 27 September 2017 (2017-09-27), pages 1376155 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007633A (zh) * 2019-02-13 2022-02-01 血管基因治疗公司 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对

Also Published As

Publication number Publication date
JP7809324B2 (ja) 2026-02-02
EP3941512A1 (en) 2022-01-26
EP3941512A4 (en) 2022-12-21
KR20220015375A (ko) 2022-02-08
US20220249621A1 (en) 2022-08-11
WO2020190977A1 (en) 2020-09-24
CA3133437A1 (en) 2020-09-24
JP2022525223A (ja) 2022-05-11
AU2020241963A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US11866509B2 (en) Humanized antibodies against CEACAM1
KR102777244B1 (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
JP6591428B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP7809324B2 (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
JP2018522850A (ja) Ｐｄ−ｌ１アンタゴニスト併用療法
JP2019513737A (ja) がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
JP2025060639A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
TW202417479A (zh) 用於治療癌症之抗-pd-1活性劑、抗-tim-3活性劑及抗-lag-3活性劑之組合療法
US20240199758A1 (en) Method for allowing immune cells infiltration in tumors
US20250123284A1 (en) Diagnostic methods for cancer using ephrinb2 expression
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
CN116134155A (zh) 通过施用pd-1抑制剂治疗癌症的方法
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
KR20250094749A (ko) 암을 치료하기 위한 il-12 유전자 요법 및 면역 체크포인트 억제제 조합물
WO2025245489A1 (en) Treatment of tumors in subjects having fgl-1 positive samples
CN120187746A (zh) 用于治疗brca阴性/同源修复正常癌症的il-12基因疗法
HK40109234A (zh) 用於治疗癌症的方法和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220114